Kiromic Biopharma, Inc. (KRBP) SEC Filing 8-K Material Event for the period ending Tuesday, March 14, 2023

Kiromic Biopharma, Inc.

CIK: 1792581 Ticker: KRBP

View differences made from one to another to evaluate Kiromic Biopharma, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Kiromic Biopharma, Inc..


Assess how Kiromic Biopharma, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Kiromic Biopharma, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2023 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 8-K Corporate News

Ticker: KRBP
CIK: 1792581
Form Type: 8-K Corporate News
Accession Number: 0001104659-23-034000
Submitted to the SEC: Fri Mar 17 2023 5:15:07 PM EST
Accepted by the SEC: Fri Mar 17 2023
Period: Tuesday, March 14, 2023
Industry: Biological Products No Disgnostic Substances
  1. Listing Status

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: